PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)

被引:0
|
作者
Chen, Tom Wei-Wu [1 ]
Dai, Ming-Shen [2 ]
Chang, Dwang-Ying [1 ]
Lin, Ching-Hung [3 ]
Chen, I-Chun [3 ]
Wang, Ming-Yang [1 ]
Huang, Ling-Yi [4 ]
Hsu, An [4 ]
Zhuo, De-Wei [4 ]
Tan, Kien Thiam [4 ]
Lu, Yen-Jung [4 ]
Chang, Shu-Han [1 ]
Cheng, Ann-Lii [3 ]
Lu, Yen-Shen [1 ]
机构
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Triserv Gen Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[4] ACT Genom Co Ltd, Taipei, Taiwan
关键词
D O I
10.1158/1538-7445.SABCS19-P5-01-21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P5-01-21
引用
收藏
页数:3
相关论文
共 46 条
  • [1] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study
    Goetz, Matthew P.
    Gal-Yam, Einav
    Stover, Daniel
    Sammons, Sarah L.
    Graff, Stephanie L.
    Wang, Grace
    Cristofanilli, Massimo
    Riordan, Gary
    Sloane, Hillary S.
    Carroll, Dominic
    Plourde, Paul V.
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
    Damodaran, Senthil
    Moore, Halle
    O'Sullivan, Ciara C.
    Plourde, Paul V.
    Riordan, Gary
    Sloane, Hillary S.
    Tripathy, Debu
    Carroll, Dominic
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2-advanced breast cancer.
    Fuentes Antras, Jesus
    Garcia-Barberan, Vanesa
    Gonzalo, Irene
    Moreno, Fernando
    Lopez-Cade, Igor
    Ramirez-Ruda, Carmen
    Bueno, Oskia
    Ascaso del Rio, Ana
    Pascual, Alejandro
    Ocana, Alberto
    Caldes, Trinidad
    Angel Garcia-Saenz, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)
    Meisel, Jane
    Sammons, Sarah L.
    Shanahan, Kelly
    Pluard, Timothy
    Kozlowski, Monica
    Carroll, Dominic
    Attias, Elizabeth
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Incidence and outcomes among patients with HR+/HER2-metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review
    Dempsey, Naomi
    Chamorro, Yolcar
    Tolman, Dana
    Sandoval-Leon, Ana Cristina
    Drusbosky, Leylah
    Lewis, Courtney
    Ahluwalia, Manmeet Singh
    Mahtani, Reshma L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
    Zhang, Qiang
    Qin, Weijun
    D'Amico, Paolo
    Jiao, Jianhua
    Davis, Andrew A.
    Gerratana, Lorenzo
    Donahue, Jeannine
    Reduzzi, Carolina
    Manai, Marwa
    Jacob, Saya
    Zhang, Youbin
    Flaum, Lisa E.
    Behdad, Amir
    Cristofanilli, Massimo
    Platanias, Leonidas C.
    Shah, Ami N.
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Dynamic development of ESR1 mutations in circulating tumor DNA (ctDNA) is associated with prognosis of patients with metastatic breast cancer (MBC)
    Zhang, Qiang
    Jiao, Jianhua
    Gerratana, Lorenzo
    D'Amico, Paolo
    Singhal, Seema
    Zhang, Youbin
    Davis, Andrew A.
    Shah, Ami N.
    Gradishar, William
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
    Gerratana, Lorenzo
    Davis, Andrew A.
    Velimirovic, Marko
    Clifton, Katherine
    Hensing, Whitney L.
    Shah, Ami N.
    Dai, Charles S.
    Reduzzi, Carolina
    D'Amico, Paolo
    Wehbe, Firas
    Medford, Arielle
    Wander, Seth A.
    Gradishar, William J.
    Behdad, Amir
    Puglisi, Fabio
    Ma, Cynthia X.
    Bardia, Aditya
    Cristofanilli, Massimo
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [9] Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
    Lorenzo Gerratana
    Andrew A. Davis
    Marko Velimirovic
    Katherine Clifton
    Whitney L. Hensing
    Ami N. Shah
    Charles S. Dai
    Carolina Reduzzi
    Paolo D’Amico
    Firas Wehbe
    Arielle Medford
    Seth A. Wander
    William J. Gradishar
    Amir Behdad
    Fabio Puglisi
    Cynthia X. Ma
    Aditya Bardia
    Massimo Cristofanilli
    Breast Cancer Research, 25
  • [10] Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2-metastatic breast cancer: Incidence and outcomes with targeted therapy.
    Dempsey, Naomi
    Bhatt, Priya
    Lewis, Courtney
    Tolman, Dana
    Chamorro, Yolcar
    Rubens, Muni
    Carcas, Lauren
    Sandoval-Leon, Ana Cristina
    Ahluwalia, Manmeet Singh
    Mahtani, Reshma L.
    Harpalani, Natasha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)